← Adapthealth overview

Adapthealth vs Huadong Medicine: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Adapthealth Corp (AHCO)

Q3 2026
▼2▲1

AdaptHealth Cuts 2026 Outlook, Sells Diabetes Unit, Swaps CFO

  • Q2 miss and huge 2026 guidance cut AdaptHealth badly missed second-quarter sales and profit, then slashed its 2026 revenue forecast to about $2.87 billion from $3.45–3.52 billion. The stock fell roughly 42–46% as investors lost confidence in how fast the core business is growing.

    This is the single biggest new force behind AHCO's price drop this period.

  • Negative free cash flow and securities investigation Free cash flow turned negative at $48.4 million for the first half, down from positive $73.3 million a year earlier, partly due to a costly West Coast contract. A law firm opened an investigation into whether AdaptHealth misled investors, adding legal uncertainty.

    Cash flow weakness and legal risk are new, concrete reasons investors are selling.

  • Selling diabetes unit to Cardinal Health for $235 million AdaptHealth agreed to sell its diabetes business to Cardinal Health for $235 million in cash. Management says this sharpens focus on sleep, respiratory and home medical equipment, and gives money to pay down debt and reinvest in the core.

    This is a major new strategic move that could support the stock by simplifying the company.

  • New CFO named as leadership changes AdaptHealth named Harriss Currie as its new chief financial officer, replacing Jason Clemens. A fresh CFO could bring new discipline, but the change comes right after a guidance shock, so investors may wait to see how it plays out.

    A new CFO is a new event that could affect how investors view the company's financial credibility.

August 2026
▼2▲1

AdaptHealth Cuts 2026 Outlook, Sells Diabetes Unit, Swaps CFO

  • Q2 miss and huge 2026 guidance cut AdaptHealth badly missed second-quarter sales and profit, then slashed its 2026 revenue forecast to about $2.87 billion from $3.45–3.52 billion. The stock fell roughly 42–46% as investors lost confidence in how fast the core business is growing.

    This is the single biggest new force behind AHCO's price drop this period.

  • Negative free cash flow and securities investigation Free cash flow turned negative at $48.4 million for the first half, down from positive $73.3 million a year earlier, partly due to a costly West Coast contract. A law firm opened an investigation into whether AdaptHealth misled investors, adding legal uncertainty.

    Cash flow weakness and legal risk are new, concrete reasons investors are selling.

  • Selling diabetes unit to Cardinal Health for $235 million AdaptHealth agreed to sell its diabetes business to Cardinal Health for $235 million in cash. Management says this sharpens focus on sleep, respiratory and home medical equipment, and gives money to pay down debt and reinvest in the core.

    This is a major new strategic move that could support the stock by simplifying the company.

  • New CFO named as leadership changes AdaptHealth named Harriss Currie as its new chief financial officer, replacing Jason Clemens. A fresh CFO could bring new discipline, but the change comes right after a guidance shock, so investors may wait to see how it plays out.

    A new CFO is a new event that could affect how investors view the company's financial credibility.

Latest
▼2▲1

AdaptHealth Cuts 2026 Outlook, Sells Diabetes Unit, Swaps CFO

  • Q2 miss and huge 2026 guidance cut AdaptHealth badly missed second-quarter sales and profit, then slashed its 2026 revenue forecast to about $2.87 billion from $3.45–3.52 billion. The stock fell roughly 42–46% as investors lost confidence in how fast the core business is growing.

    This is the single biggest new force behind AHCO's price drop this period.

  • Negative free cash flow and securities investigation Free cash flow turned negative at $48.4 million for the first half, down from positive $73.3 million a year earlier, partly due to a costly West Coast contract. A law firm opened an investigation into whether AdaptHealth misled investors, adding legal uncertainty.

    Cash flow weakness and legal risk are new, concrete reasons investors are selling.

  • Selling diabetes unit to Cardinal Health for $235 million AdaptHealth agreed to sell its diabetes business to Cardinal Health for $235 million in cash. Management says this sharpens focus on sleep, respiratory and home medical equipment, and gives money to pay down debt and reinvest in the core.

    This is a major new strategic move that could support the stock by simplifying the company.

  • New CFO named as leadership changes AdaptHealth named Harriss Currie as its new chief financial officer, replacing Jason Clemens. A fresh CFO could bring new discipline, but the change comes right after a guidance shock, so investors may wait to see how it plays out.

    A new CFO is a new event that could affect how investors view the company's financial credibility.

Huadong Medicine Co Ltd (000963.CS)

Q3 2026
▲2▼1

Procurement loss and profit dip offset aesthetics and FDA wins

  • Procurement loss threatens core revenue Huadong lost bids for four products, including core indobufen tablets, with 2025 sales of 4.634 billion yuan — 10.62% of total revenue. Losing hospital access will likely cut future sales, a real drag on the stock.

    This is the biggest negative force this period, directly threatening a large chunk of revenue.

  • Aesthetic products gain China and EU approvals Huadong's subsidiary won EU CE certification for an injectable aesthetic product and China approval for MaiLi Precise, the first injectable for under-eye hollows. These open new markets and support future growth, though near-term financial impact is small.

    New product approvals are a positive growth driver that can lift investor sentiment.

  • FDA fast track for innovative cancer drug HDM2005, a first-in-class ROR1-targeting ADC for mantle cell lymphoma, received FDA Fast Track designation. This speeds up development and review, boosting the company's innovative drug story and long-term potential.

    A regulatory win for a novel cancer drug adds credibility and future revenue potential.

  • Interim profit up but quarterly slowdown First-half net profit rose 2.53% to 1.861 billion yuan, with a 3.5 yuan per 10 shares dividend. But second-quarter profit fell 14% from the first quarter, and margins weakened, so the market may worry about momentum.

    The earnings report is the key financial update, showing both stability and a concerning quarterly decline.

August 2026
▲2▼1

Procurement loss and profit dip offset aesthetics and FDA wins

  • Procurement loss threatens core revenue Huadong lost bids for four products, including core indobufen tablets, with 2025 sales of 4.634 billion yuan — 10.62% of total revenue. Losing hospital access will likely cut future sales, a real drag on the stock.

    This is the biggest negative force this period, directly threatening a large chunk of revenue.

  • Aesthetic products gain China and EU approvals Huadong's subsidiary won EU CE certification for an injectable aesthetic product and China approval for MaiLi Precise, the first injectable for under-eye hollows. These open new markets and support future growth, though near-term financial impact is small.

    New product approvals are a positive growth driver that can lift investor sentiment.

  • FDA fast track for innovative cancer drug HDM2005, a first-in-class ROR1-targeting ADC for mantle cell lymphoma, received FDA Fast Track designation. This speeds up development and review, boosting the company's innovative drug story and long-term potential.

    A regulatory win for a novel cancer drug adds credibility and future revenue potential.

  • Interim profit up but quarterly slowdown First-half net profit rose 2.53% to 1.861 billion yuan, with a 3.5 yuan per 10 shares dividend. But second-quarter profit fell 14% from the first quarter, and margins weakened, so the market may worry about momentum.

    The earnings report is the key financial update, showing both stability and a concerning quarterly decline.

Latest
▲2▼1

Procurement loss and profit dip offset aesthetics and FDA wins

  • Procurement loss threatens core revenue Huadong lost bids for four products, including core indobufen tablets, with 2025 sales of 4.634 billion yuan — 10.62% of total revenue. Losing hospital access will likely cut future sales, a real drag on the stock.

    This is the biggest negative force this period, directly threatening a large chunk of revenue.

  • Aesthetic products gain China and EU approvals Huadong's subsidiary won EU CE certification for an injectable aesthetic product and China approval for MaiLi Precise, the first injectable for under-eye hollows. These open new markets and support future growth, though near-term financial impact is small.

    New product approvals are a positive growth driver that can lift investor sentiment.

  • FDA fast track for innovative cancer drug HDM2005, a first-in-class ROR1-targeting ADC for mantle cell lymphoma, received FDA Fast Track designation. This speeds up development and review, boosting the company's innovative drug story and long-term potential.

    A regulatory win for a novel cancer drug adds credibility and future revenue potential.

  • Interim profit up but quarterly slowdown First-half net profit rose 2.53% to 1.861 billion yuan, with a 3.5 yuan per 10 shares dividend. But second-quarter profit fell 14% from the first quarter, and margins weakened, so the market may worry about momentum.

    The earnings report is the key financial update, showing both stability and a concerning quarterly decline.